Imiquimod

Imiquimod (Aldara)  is licensed for the treatment of superficial basal cell carcinomas giving response rates of over 80% when used 5 times a week for 6 weeks.

There is little data on its use in individuals with Gorlin Syndrome but from clinical experience it does seem to be helpful in treating small superficial lesions. Side effects include making the skin go red and crusty, sometimes causing erosions and ulceration. Occasionally flu like symptoms can be experienced.

Ref: Telfer NR, Colver GB and Morton CA. Guidelines in the management of basal cell carcinoma. Br Journal of Dermatology 2008, 159: 35 - 48

Further information can be accessed courtesy of British Association of Dermatologists Patient Information Leaflet

Next Review January 2016

Information Standard Logo 


 Originally produced by Professor P. A. Farndon, Clinical Geneticist, Jim Costello (deceased) and Margaret Costello.  We are reliant on a team of medical advisors for the clinical content of the website. We are grateful for their continuing support. 
Gorlin Syndrome Group is Registered Charity in the UK - No 1096361 
 
Checkout
Gorlin Syndrome community on HealthUnlocked
website security